Osimertinib and Ondansetron (Zofer 8 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Potential additive QT prolongation and serious ventricular arrhythmia risk.
Clinical significance and safety
Osimertinib and Zofer 8 mg can both prolong cardiac repolarisation; the partner medicine’s label includes reports or risk of torsades de pointes. The osimertinib label advises avoiding such combinations when feasible and using ECG monitoring if they cannot be avoided. The combined clinical effect has not been directly established for every pair; risk assessment must include electrolytes, heart disease and the full regimen.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.